FDA Accepts Cabozantinib Application for Advanced HCC

May 30, 2018 – The FDA has accepted a supplemental new drug application (sNDA) for cabozantinib as a treatment for patients with previously-treated advanced hepatocellular carcinoma (HCC), according to a statement from the company developing the therapy, Exelixis. The application for cabozantinib was based on findings from the phase III CELESTIAL trial, in which overall survival (OS) was improved by 2.2 months with cabozantinib versus placebo. Median OS with … (leggi tutto)